Why the study?
Delivering therapeutic agents specifically to the injured heart remains a significant challenge despite emerging therapies for injured myocardium repair.
Answers are grounded in this paper and cite their sources.
Nanoparticle-based drug delivery systems offer a promising approach for targeted therapy in heart failure and myocardial injury.
Heart failure secondary to myocardial injuries is a leading cause of death worldwide. Recently, a growing number of novel therapies have emerged for injured myocardium repairment. However, delivering therapeutic agents specifically to the injured heart remains a significant challenge. Nanoparticles are the most commonly used vehicles for targeted drug delivery. Various nanoparticles have been synthesized to deliver drugs and other therapeutic molecules to the injured heart via passive or active targeting approaches, and their targeting specificity and therapeutic efficacies have been investigated. Here, we summarized nanoparticle-based, cardiac-specific drug delivery systems, their potency for treating heart diseases, and the mechanisms underlying these cardiac-targeting strategies. We also discussed the clinical studies that have employed nanoparticle-based cardiac-specific drug delivery.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: